Gyre Therapeutics Inc.
GYRE | NASDAQ
$4.55
-$1.86 (-29.02%)
At close: Oct 30, 2026, 4:00 PM ET
$5.10
+$0.55 (+12.09%)
Pre-market:
Nov 2, 2026, 4:52 AM ET
-29.02%
(1D)No price chart data available for 1D timeframe.
Rating
43.8
+3.6 ptsFundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #429/1028 (Top 42%)
Key Statistics
Market Data
Market Cap $482.98M
1D Range
4.51 6.25
52W Range
4.51 8.76
Valuation (TTM)
PE -22.75
PB 3.71
EV/EBITDA -29.35
Valuation (NTM)
Forward PE 87.00
Forward PEG 0.07
Price Target $17.00
Cash Flow
FCF Yield -3.5%
SBC Adj. FCF Yield -5.1%
SBC Impact -46.6%
Margins
Gross Margin 94.3%
Operating Margin -14.0%
FCF Margin -14.1%
Growth (CAGR)
Revenue 3Y | 5Y 2.2% |
84.9%
Dil EPS 3Y | 5Y 106.6% |
31.0%
FCF 3Y | 5Y -175.8% |
43.8%
Returns
ROA -8.7%
ROE -15.8%
ROIC -9.7%
Financial Health
Net Cash
$74.8M
Current Ratio 4.26
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The compan...
Sector Healthcare
Industry Biotechnology
Employees 625
IPO Date Apr 12, 2006
Website www.gyretx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove GYRE